<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00449202</url>
  </required_header>
  <id_info>
    <org_study_id>MAN-OE-OS-03</org_study_id>
    <nct_id>NCT00449202</nct_id>
  </id_info>
  <brief_title>Phase 2a Obesity Study of Oral Doses of Oleoyl-Estrone (MP-101)</brief_title>
  <official_title>A Phase 2a Randomized, Double-Blind, Placebo Controlled, Parallel Group, Safety and Efficacy Study of Two 14 Day Cycles of Oral Doses of Oleoyl-Estrone (MP-101) in Obese Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Manhattan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Manhattan Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, preliminary efficacy, and
      pharmacokinetics of two 14-day cycles of escalating oral doses of MP 101 in 100 obese adult
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2006</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the preliminary efficacy</measure>
  </secondary_outcome>
  <enrollment>100</enrollment>
  <condition>Obesity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oleoyl-estrone (MP 101)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be a male or female between the ages of 18 and 65 years, inclusive

          -  Female subjects must be either surgically sterile or at least 2 years postmenopausal

          -  Have a BMI of 27 - 38.9, inclusive

          -  Have a stable weight for the past 30 days per subject report

          -  Be otherwise healthy and have an acceptable medical history

          -  Have negative urinalysis test results for drugs of abuse and alcohol

          -  Have the ability to understand the requirements of the study, have provided written
             informed consent and agree to abide by the study restrictions

          -  Exhibit stable behavior patterns with regard to smoking and exercise

          -  Subject who has at least one factor of the metabolic syndrome

        Exclusion Criteria:

          -  Be pregnant or nursing

          -  Have taken exclusionary medication in the past 30 days

          -  Have any clinically significant abnormal laboratory test as determined by the
             investigator

          -  Have a clinically significant illness during the 30 days before enrollment

          -  Have a history of testing positive for Hepatitis B virus, Hepatitis C virus, or HIV

          -  Have a confirmed diagnosis or history of cancer, with the exception of nonmelanoma
             skin cancer

          -  Have a previous diagnosis of diabetes

          -  Be otherwise unsuitable for the study, in the opinion of the investigator

          -  Have an allergy to safflower seeds or its byproducts (e.g., safflower oil)

          -  Have any postmenopausal bleeding within the last 6 months

          -  Have been involved in a formal or informal (self-imposed) diet regimen within the last
             30 days

          -  Currently working night shifts

          -  Have a history of known multiple miscarriages
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pennington Biomedical Research</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swiss Pharma Contract</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2007</study_first_submitted>
  <study_first_submitted_qc>March 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2007</study_first_posted>
  <last_update_submitted>March 16, 2007</last_update_submitted>
  <last_update_submitted_qc>March 16, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrone</mesh_term>
    <mesh_term>Estropipate</mesh_term>
    <mesh_term>Oleoyl-estrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

